Status:
COMPLETED
Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Gamma Medica-Ideas
Conditions:
Breast Cancer
Eligibility:
FEMALE
35-45 years
Brief Summary
This study is to examine the effects of menstrual cycle, hormone therapy, and the use of tamoxifen on Tc-99m sestamibi uptake.
Eligibility Criteria
Inclusion
- Arm 1
- age 35-45
- have regular menstrual cycles as defined by having menstrual cycle length of 25-31 days, with menstrual flow of 2-7 days, and no intermenstrual spotting or bleeding.
- have had a negative screening mammogram within one year prior to the MBI studies that is available for comparison.
Exclusion
- currently using any exogenous hormones (e.g., hormonal contraceptives, sex steroid hormones) or any estrogen receptor modulating drugs (e.g., tamoxifen, raloxifene) or any aromatase inhibitors
- have a personal history of any cancer, except non-melanomatous skin cancer
- unable to understand and sign the consent form
- pregnant or lactating
- physically unable to sit upright and still for 30 minutes
- Arm 2
- Inclusion Criteria:
- scheduled to begin one of the following regimens of HT:
- Any dosage of any formulation of systemic estrogen therapy in the setting of a prior hysterectomy
- Any dosage of continuous estrogen plus monthly, cyclic progesterone therapy where the progesterone therapy is the oral, micronized formulation
- had a negative screening mammogram within one year prior to the MBI studies that is available for comparison.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00943527
Start Date
January 1 2008
End Date
January 1 2012
Last Update
January 25 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905